Paolo Tarantino: The OXEL trial is out on Nature Communications

Paolo Tarantino, Medical Oncologist and Research Fellow at Dana-Farber Cancer Institute, shared a post on X/Twitter:

“The OXEL trial, led by Filipa Lynce, is out on Nature Communications. Among 45 pts with residual TNBC after NAT, adjuvant Nivolumab/Capecitabine were well tolerated, increased peripheral immune score and led to numerically improved 2 year iDFS (91%) vs nivo (47%) or cape alone (53%). “

Source: Paolo Tarantino/X